novedex

Alberto86 · 20-09-2010, 11:01 AM

Quote:

Originariamente inviato da DjBaldux

Spero che metterselo in testa ogni giorno non sia troppo controproducente

Quote:

Originariamente inviato da DjBaldux

keto oil al 2% se non mi sbaglio.
Ovviamente lo uso per l'aga, non vorrei perdere i capelli a 20 anni

non dovresti avere problemi importanti con un prodotto ad uso topico anche se quando l'ho usai io notai effettivamente dei problemi....il mio cosniglio è di non abusarne comunque..

Alberto86 · 20-09-2010, 11:02 AM

Quote:

Originariamente inviato da Alberto86

non dovresti avere problemi importanti con un prodotto ad uso topico anche se quando l'ho usai io notai effettivamente dei problemi....il mio cosniglio è di non abusarne comunque..

mi scuso per come ho scritto ma non mi fa editare

albynumber01 · 26-12-2010, 01:46 PM

Riuppo questa discussione per evitare di aprirne un'altra!

Siccome sto cercando di capire per bene questo argomento e sn alle prime armi ho un po di confusione

Online ho trovato questa ricerca riguardo al Novedex

Novedex XT Clinical Trial
OHIO RESEARCH GROUP
Ziegenfuss T.N., Mendel R.W., and Hofheins J.E. Safety and Efficacy of a Naturally-Occurring, Orally Administered, Aromatase Inhibitor in Healthy Men. Ohio Research Group of Exercise Science and Sports Nutrition. Wadsworth, Ohio 44281, USA. tim@ohioresearchgroup.comThis email address is being protected from spam bots, you need Javascript enabled to view it

Rationale: In healthy men, it is known that blocking estrogen formation stimulates the HPT axis to increase in vivo testosterone production. Recently, a new class of dietary supplements has appeared that claim to inhibit the aromatase enzyme (i.e., decrease the transformation of aromatizable androgens [androstenedione, DHEA, testosterone] into estrogens [estriol, estrone, estradiol]), thus stimulating an increase in testosterone formation.

Purpose: The purpose of this pilot study was to examine the effects of a popular aromatase inhibitor, Novedex XTÔ (NOV-XT), on selected hormonal responses (total testosterone [TT], bioavailable testosterone [BT] and estradiol [E2]), as well as serum and plasma markers of renal, hepatic, and hematological function.

Methods: Using an open-label, proof-of-concept design, five eugonadal men (mean ± superdrol age, height, weight, body fat: 31.6 ± 2.8 yr, 174.3 ± 1.8 cm, 84.3 ± 3.8 kg, 11.2 ± 3.3 %) ingested 4 capsules of NOV-XT prior to bed for 28 consecutive days. According to the manufacturer, each capsule of NOV-XT contains 60 mg of a proprietary blend of three naturally-occurring aromatase inhibitors: 6, 17-keto-etiocholeve-3-ol tetrahydropyranol, 3, 17-keto-etiochol-triene, and 3’,5,7-trihydroxy-4’-methoxyflavone (supplements were provided by an FDA-registered, pharmaceutically licensed manufacturer; confirmation by an external laboratory is pending). Blood samples obtained at baseline (prior to supplementation), and at weekly intervals thereafter for 28 days, were analyzed for TT, BT, and E2 by radioimmunometric and chemilluminetric assays. Subjects were required to maintain their normal dietary and training patterns during the study. All blood samples were obtained at the same time of day (0700-0900) to minimize diurnal variation. Hormone concentrations were statistically analyzed by ANOVA and Tukey’s HSD post-hoc test. Dependent t-tests were used to compare changes in blood chemistries. Statistical significance was accepted at p<0.05.

Results: Compared to baseline, NOV-XT administration rapidly and significantly increased TT and BT. Mean changes from baseline for TT after one, two, three, and four weeks of NOV-XT administration were: +145% (p<0.006), +183% (p<0.0005), +232% (p<0.0002), and +240% (p<0.0002), respectively. Mean changes from baseline for BT after one, two, three, and four weeks of NOV-XT administration were: +300% (p<0.01), +402% (p<0.0009), +511% (p<0.0002), and +528% (p<0.0002), respectively. Despite these large increases in TT and BT, no significant aromatization to estradiol occurred (i.e., E2 concentrations remained unchanged). No significant changes in clinical blood chemistries (fasting glucose, BUN, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, chloride, calcium, albumin, globulin, CO2, total protein, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol) or systemic hemodynamics (heart rate, systolic blood pressure, diastolic blood pressure) were observed, nor were any adverse events noted during the study.

Variable Baseline Day 7 Day 14 Day 21 Day 28
Testosterone (ng/dL) 517 (162) 1265 (252) * 1515 (212) * 1714 (322) * 1758 (435) *
Bio T (ng/dL) 159 (57) 636 (265) * 798 (94) * 971 (226) * 998 (210) *
Estradiol (pg/mL) 22 (3) 19 (9) 16 (9) 19 (11) 19 (9)
Glucose (mg/dL) 90 (4) 87 (10)
BUN:Cr 17 (5) 17 (4)
Bilirubin (mg/dL) 0.8 (0.5) 0.9 (0.5)
ALP (IU/L) 84 (32) 67 (43)
AST (IU/L) 27 (7) 27 (8)
ALT (IU/L) 29 (11) 31 (15)
Chol (mg/dL) 156 (19) 163 (27)
TAG (mg/dL) 74 (22) 72 (19)
HDL (mg/dL) 54 (3) 51 (9)
LDL (mg/dL) 87 (18) 97 (20)
SBP (mm Hg) 124 (5) 124 (11)
DBP (mm Hg) 75 (6) 74 (14)

L'esito sembrerebbe ottimo, ma quanto è attendibile?

Strumenti Discussione
Visualizza Versionee Stampabile Invia Pagina via Email
Modalità Visualizzazione
In Modalità lineare Modalità ibrido In Modalità elencata

	(#3)
albynumber01 All the Truth Member Messaggi: 617 Data registrazione: Jan 2009	26-12-2010, 01:46 PM Riuppo questa discussione per evitare di aprirne un'altra! Siccome sto cercando di capire per bene questo argomento e sn alle prime armi ho un po di confusione Online ho trovato questa ricerca riguardo al Novedex Novedex XT Clinical Trial OHIO RESEARCH GROUP Ziegenfuss T.N., Mendel R.W., and Hofheins J.E. Safety and Efficacy of a Naturally-Occurring, Orally Administered, Aromatase Inhibitor in Healthy Men. Ohio Research Group of Exercise Science and Sports Nutrition. Wadsworth, Ohio 44281, USA. tim@ohioresearchgroup.comThis email address is being protected from spam bots, you need Javascript enabled to view it Rationale: In healthy men, it is known that blocking estrogen formation stimulates the HPT axis to increase in vivo testosterone production. Recently, a new class of dietary supplements has appeared that claim to inhibit the aromatase enzyme (i.e., decrease the transformation of aromatizable androgens [androstenedione, DHEA, testosterone] into estrogens [estriol, estrone, estradiol]), thus stimulating an increase in testosterone formation. Purpose: The purpose of this pilot study was to examine the effects of a popular aromatase inhibitor, Novedex XTÔ (NOV-XT), on selected hormonal responses (total testosterone [TT], bioavailable testosterone [BT] and estradiol [E2]), as well as serum and plasma markers of renal, hepatic, and hematological function. Methods: Using an open-label, proof-of-concept design, five eugonadal men (mean ± superdrol age, height, weight, body fat: 31.6 ± 2.8 yr, 174.3 ± 1.8 cm, 84.3 ± 3.8 kg, 11.2 ± 3.3 %) ingested 4 capsules of NOV-XT prior to bed for 28 consecutive days. According to the manufacturer, each capsule of NOV-XT contains 60 mg of a proprietary blend of three naturally-occurring aromatase inhibitors: 6, 17-keto-etiocholeve-3-ol tetrahydropyranol, 3, 17-keto-etiochol-triene, and 3’,5,7-trihydroxy-4’-methoxyflavone (supplements were provided by an FDA-registered, pharmaceutically licensed manufacturer; confirmation by an external laboratory is pending). Blood samples obtained at baseline (prior to supplementation), and at weekly intervals thereafter for 28 days, were analyzed for TT, BT, and E2 by radioimmunometric and chemilluminetric assays. Subjects were required to maintain their normal dietary and training patterns during the study. All blood samples were obtained at the same time of day (0700-0900) to minimize diurnal variation. Hormone concentrations were statistically analyzed by ANOVA and Tukey’s HSD post-hoc test. Dependent t-tests were used to compare changes in blood chemistries. Statistical significance was accepted at p<0.05. Results: Compared to baseline, NOV-XT administration rapidly and significantly increased TT and BT. Mean changes from baseline for TT after one, two, three, and four weeks of NOV-XT administration were: +145% (p<0.006), +183% (p<0.0005), +232% (p<0.0002), and +240% (p<0.0002), respectively. Mean changes from baseline for BT after one, two, three, and four weeks of NOV-XT administration were: +300% (p<0.01), +402% (p<0.0009), +511% (p<0.0002), and +528% (p<0.0002), respectively. Despite these large increases in TT and BT, no significant aromatization to estradiol occurred (i.e., E2 concentrations remained unchanged). No significant changes in clinical blood chemistries (fasting glucose, BUN, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase, sodium, potassium, chloride, calcium, albumin, globulin, CO2, total protein, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, VLDL-cholesterol) or systemic hemodynamics (heart rate, systolic blood pressure, diastolic blood pressure) were observed, nor were any adverse events noted during the study. Variable Baseline Day 7 Day 14 Day 21 Day 28 Testosterone (ng/dL) 517 (162) 1265 (252) * 1515 (212) * 1714 (322) * 1758 (435) * Bio T (ng/dL) 159 (57) 636 (265) * 798 (94) * 971 (226) * 998 (210) * Estradiol (pg/mL) 22 (3) 19 (9) 16 (9) 19 (11) 19 (9) Glucose (mg/dL) 90 (4) 87 (10) BUN:Cr 17 (5) 17 (4) Bilirubin (mg/dL) 0.8 (0.5) 0.9 (0.5) ALP (IU/L) 84 (32) 67 (43) AST (IU/L) 27 (7) 27 (8) ALT (IU/L) 29 (11) 31 (15) Chol (mg/dL) 156 (19) 163 (27) TAG (mg/dL) 74 (22) 72 (19) HDL (mg/dL) 54 (3) 51 (9) LDL (mg/dL) 87 (18) 97 (20) SBP (mm Hg) 124 (5) 124 (11) DBP (mm Hg) 75 (6) 74 (14) L'esito sembrerebbe ottimo, ma quanto è attendibile?